Company Overview of PharmAkea, Inc.
PharmAkea, Inc. operates as a biopharmaceutical company in California. The company discovers and develops small molecule therapeutics for cancer and fibrotic diseases. Its lead program includes a small molecule LOXL2 inhibitor. PharmAkea Inc. has a strategic collaboration with Celgene Corporation to leverage PharmAkea's proprietary drug discovery platform and novel small molecule therapies targeting fibrotic diseases. The company was founded in 2012 and is based in San Diego, California.
3030 Bunker Hill
San Diego, CA 92109
Founded in 2012
Key Executives for PharmAkea, Inc.
PharmAkea, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
November 18, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PharmAkea, Inc., please visit www.pharmakea.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.